Half-year report · Q2
7133.TEDINET S100UP3P
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks11 of 11 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥8.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Operating income | ¥449m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥435m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥717m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥435m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥291m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥441m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥291m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥6.9bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥6.4bn | at 2024-03-31 | Cons. | Assets |
| Total liabilities | ¥5.0bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥4.7bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.9bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥1.6bn | at 2024-03-31 | Cons. | Net assets |
| Cash and deposits | ¥889m | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥688m | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥889m | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥688m | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥188m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥707m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥188m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥201m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥539m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥41.03 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥62.05 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥39.62 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥59.26 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 28.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 25.9% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 19
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥420,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥420,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥4m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥296m |
| jpcrp040300-q2r_E37198-000Home Visit Pharmacist Servicereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.4bn |
| jpcrp040300-q2r_E37198-000Home Visit Pharmacist Servicereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.4bn |
| jpcrp040300-q2r_E37198-000Home Visit Pharmacist Servicereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥277m |
| jpcrp040300-q2r_E37198-000Kirari Primereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥544m |
| jpcrp040300-q2r_E37198-000Kirari Primereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥544m |
| jpcrp040300-q2r_E37198-000Kirari Primereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥338m |
| jpcrp040300-q2r_E37198-000Primary Care Homereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥759m |
| jpcrp040300-q2r_E37198-000Primary Care Homereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥759m |
| jpcrp040300-q2r_E37198-000Primary Care Homereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥134m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥4.7bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥4.7bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥749m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥4.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥4.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥745m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 331
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人ト ー マ ツ | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)宮 本 芳 樹 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)下 平 雅 和 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | CurrentYTDDuration | 4719387000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 8285853000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 435136000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 716880000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 291328000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 441027000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 291328000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 441027000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 1934866000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 1643125000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 6900129000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 6354996000 | JPY |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 41.03 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 62.05 | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | 39.62 | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | 59.26 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.280 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.259 | |
| Net cash provided by used in operating activities (5-year summary) | CurrentYTDDuration | 187606000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 706642000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYTDDuration | -188082000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -1125097000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYTDDuration | 201360000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | 538778000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant | 888896000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 688010000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 7248400 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 7252000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 7248400 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 7252000 | |
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 1366000 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.1924 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 900000 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.1267 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 840000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.1183 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 699000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0985 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 507000 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0714 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 500000 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0705 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 334000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0471 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 216000 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 11 of 11 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |